Skip to main content
. Author manuscript; available in PMC: 2019 Mar 10.
Published in final edited form as: Br J Nutr. 2017 May;117(10):1403–1413. doi: 10.1017/S000711451700143X

Table 5.

Blood markers of CVD risk following each 6-week treatment period* (Mean values with their standard errors; n 20)

Soya protein
Baseline
0 g/d (control)
25 g/d
50 g/d
P
Mean SEM Mean SEM Mean SEM Mean SEM For treatment effect For period effect

Glucose (mmol/l) 4.9 0.1 5.0 0.1 5.1 0.1 5.1 0.1 0.14 0.15
log Insulin (μIU/I) 0.70 0.04 0.73 0.04 0.69 0.04 0.73 0.04 0.74 0.43
TC (mmol/l) 5.1 0.2 4.9 0.1 5.0 0.1 4.9 0.1 0.64 0.06
HDL-cholesterol (mmol/l) 1.4 0.1 1.4 0.04 1.4 0.04 1.4 0.4 0.26 0.25
TC:HDL-cholesterol 3.8 0.2 3.8 0.1 3.7 0.1 3.7 0.1 0.57 0.87
LDL-cholesterol (mmol/l) 3.1 0.1 3.0 0.1 3.0 0.1 2.9 0.1 0.85 0.40
log TAG (mmol/l) 2.0 0.04 2.0 0.03 2.0 0.03 2.0 0.03 0.75  0.003a
Non-HDL-cholesterol (mmol/l) 3.7 0.2 3.5 0.1 3.6 0.1 3.6 0.1 0.67  0.02b
log CRP (mg/l) 0.16 0.10 0.11 0.07 0.18 0.07 0.11 0.07 0.36  0.02c

TC, total cholesterol; CRP, C-reactive protein.

a

Period 1 values significantly lower than period 3 values in post hoc comparisons (Tukey-adjusted P = 0.002);

b

period 1 values significantly lower than period 3 values in post hoc comparisons (Tukey-adjusted P = 0.02);

c

period 1 values significantly higher than period 2 and period 3 values in post hoc comparisons (Tukey-adjusted P = 0.03 and 0.05, respectively).

*

Values were compared using the MIXED procedure (SAS version 9.4; SAS Institute Inc.).

Data represent eighteen participants; two were excluded from analyses for this treatment period due to acutely elevated CRP concentrations (i.e. CRP ≥10.5 mg/l).